Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 18:26:08 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

BioInvent Q1 2025 - Focus on BI-1808 in T-cell Lymphoma

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

BioInvent Q1 2025 - Focus on BI-1808 in T-cell Lymphoma

2025-04-30 13:26:00

Redeye comments on BioInvent’s first quarter in 2025. After our last update, BI-1808 obtained both Fast Track and Orphan Drug designations from the FDA. It is on track for a phase IIa readout by mid-year. Other programmes, including BI-1206, are also set for important readouts this year. Furthermore, the partnered asset mezagitamab moved into phase III, triggering a milestone payment.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/